US › Healthcare

Pmv Pharmaceuticals Inc (PMVP)

US · Healthcare · Biotechnology

$1.21-6.20%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-18.1M

EPS

$-0.34

EPS estimate

$-0.38

EPS came in at -0.34 against a street estimate of -0.38 — a beat of 10.5%.

Key statistics

Market cap

$101.9M

Forward P/E

0.0

P/B

1.03

Book value

$1.34

EPS (TTM)

$-1.42

52-week high

$1.91

52-week low

$1.02

50-day MA

$1.37

200-day MA

$1.29

Beta

1.35

Analyst view

Analysts rate Pmv Pharmaceuticals Inc a strong buy (6 buy, 0 hold, 0 sell out of 6) with an average price target of $4.20.

Shareholding

Insiders

2.37%

Institutions

46.43%

Largest institutional holders

Fund	Stake
BML Capital Management LLC	7.06%
TANG CAPITAL MANAGEMENT LLC	5.62%
Sio Capital Management, LLC	3.49%
Euclidean Capital LLC	3.48%
Adage Capital Partners Gp LLC	3.13%
Acadian Asset Management LLC	2.93%
Vanguard Capital Management, LLC	2.66%
ArrowMark Colorado Holdings, LLC (ArrowMark Partners)	2.60%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Pmv Pharmaceuticals Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-19.